Labor Dr. Spranger
Labor Dr. Spranger is recorded as a service provider in 22 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 22 trials · Latest update first
Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Proof-of-Concept Evaluation of Immunological Assays Using Human Blood and Urine Samples after Vaccination with StroVac
Sponsor Strathmann GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase II, Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-Free Diet
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Multi-centre, double-blind, placebo-controlled, randomised trial to prove the efficacy and safety of Silexan® (WS®1265) in patients with a major depressive episode of mild to moderate severity
Sponsor Dr. Willmar Schwabe GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Menthacarin® in the treatment of functional gastrointestinal disorders
Sponsor Dr. Willmar Schwabe GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Prospective, Interventional Study to Assess the Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon® 35,000) in Patients with Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery
Sponsor MEDA Pharma GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult and adolescent patients with moderate to severe hidradenitis suppurativa (RECHARGE-1)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult and adolescent patients with moderate to severe hidradenitis suppurativa (RECHARGE-2)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multicenter, prospective, single-arm, exploratory study to assess role of pancreatic enzyme replacement therapy (PERT) (Creon® 25,000) in patients with Pancreatic Exocrine Insufficiency (PEI) after total gastrectomy.
Sponsor BGP Products Operations GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
(ESMERALD) A phase-2A, single-centre, prospective, uncontrolled, open label, single arm, exploratory clinical study to evaluate the safety and efficacy of cutaneous AUP1602-C with foam dressing as a treatment for non-healing neuroischemic diabetic foot ulcers
Sponsor Aurealis Oy
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant cell arteritis (GCA) who are in clinical remission and eligible for treatment with glucocorticoidmonotherapy (GigAINt)
Sponsor Novartis Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering in participants with atherosclerotic cardiovascular disease (VICTORION-CHALLENGE)
Sponsor Novartis Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Labor Dr. Spranger?
The 2026-10-09 snapshot links Labor Dr. Spranger to 22 distinct CTIS trials. Recorded services include Laboratory services, archiving of blood samples for future trial-related scientific investigation, Bio marker Testing, Sample logistics. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Labor Dr. Spranger?
The most frequently recorded therapeutic areas are Gastroenterology, Hepatology, Immunology, Infectious Disease. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Labor Dr. Spranger conducted?
The linked trials record locations in 22 countries, including Germany, Poland, Austria, Spain, France. These are trial locations, not confirmed office locations or countries where Labor Dr. Spranger delivered services.
What can this page tell me about Labor Dr. Spranger's trial experience?
Browse 22 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Labor Dr. Spranger. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Labor Dr. Spranger